**Background**
Sigma ($\sigma$) receptors are unique chaperone proteins that modulate various cellular signaling pathways and are implicated in a wide range of neurological disorders and oncological processes. In the central nervous system, these receptors play a role in regulating neurotransmitter release and locomotor activity, making them significant targets for treating addiction and cognitive impairment. Furthermore, recent research has highlighted the potential of sigma receptor ligands in oncology, particularly in their ability to induce selective cytotoxicity in malignant cells. Understanding the interaction between these receptors and cellular survival mechanisms is crucial for developing targeted therapies. In this context, we will introduce a carbazole derivative and sigma receptor antagonist – Rimcazole.
**Definition**
Rimcazole (BW 234U) dihydrochloride is a carbazole derivative that acts as a sigma ($\sigma$) receptor antagonist and also binds with moderate affinity to the dopamine transporter to inhibit dopamine uptake.
**In Vitro and In Vivo Studies**
According to the Rimcazole description, this compound exhibits significant biological activity across different research models. In terms of Rimcazole biological activity, the compound has demonstrated the ability to reduce locomotor activity and sensitization. In the field of Rimcazole cancer research, in vitro studies have shown that Rimcazole (1-50 $\mu$M; 24-48 h) decreases the number of HCT-116p53 +/+ cells in a concentration-dependent manner. Furthermore, Rimcazole (50 $\mu$M; 1-24 h) dihydrochloride induces a transient accumulation of HIF-1$\alpha$ protein in cancer cells, specifically in HCT-116p53 +/+ and MDA MB 231 cells, while having no effect on normal human dermal fibroblasts. Western blot analysis of HCT-116p53 +/+ cells treated with 50 $\mu$M Rimcazole revealed that HIF-1$\alpha$ protein accumulation peaks at 6 hours and returns to normal steady-state levels within 24 hours, with no observed change in p53 protein levels. In vivo studies have further explored its effects on the reinforcing properties of cocaine injection and food presentation in rat models. In conclusion, Rimcazole is a versatile sigma receptor antagonist with potential applications in both neuropsychiatric and oncology research.
Keywords
Rimcazole, 75859-03-9, BW 234U, Sigma Receptor, Dopamine Receptor, σ, transporter, uptake, cancer, Inhibitor, inhibitor, inhibit
References
[1] Gilmore DL, et, al. Review of the pharmacological and clinical profile of rimcazole. CNS Drug Rev. Spring 2004;10(1):1-22.
[2] Achison M, et, al. HIF-1alpha contributes to tumour-selective killing by the sigma receptor antagonist rimcazole. Oncogene. 2007 Feb 22;26(8):1137-46.
[3] Matsumoto RR, et, al. Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology. 2001 Dec;41(7):878-86.
[4] Job MO, et, al. A behavioral economic analysis of the effects of rimcazole on reinforcing effects of cocaine injection and food presentation in rats. Psychopharmacology (Berl). 2019 Dec;236(12):3601-3612.